Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial

TL;DR: In this 6-month trial involving patients with type 1 diabetes, the use of a closed-loop system was associated with a greater percentage of time spent in a target glycemic range than theUse of a sensor-augmented insulin pump.

TL;DR: The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care as discussed by the authors .

TL;DR: The American Association of Clinical Endocrinology selected a task force of medical experts and staff who updated and assessed clinical questions and recommendations from the prior 2015 version of this guideline and conducted literature searches for relevant scientific papers published from January 1, 2015, through May 15, 2022 as mentioned in this paper .

TL;DR: In this article, the authors compared outcomes using a commercially available hybrid closed-loop system versus a new investigational system with features potentially useful for adolescents and young adults with type 1 diabetes.

TL;DR: Rank tests such as the two Wilcoxon tests or the Kruskal-Wallis H-test have been shown to be more robust against gross errors than that of the t-and F-tests, even in the rare case in which the suspicion of the possibility of gross errors is unfounded.

TL;DR: There remains considerable room for improving outcomes of treatment of type 1 diabetes across all age-groups and barriers to more effective use of current treatments need to be addressed and new therapies are needed to achieve optimal metabolic control in people with type 1 Diabetes.

TL;DR: It is demonstrated that impaired awareness of hypoglycemia predisposes to a sixfold increase in the frequency of severe hyp glucosecemia, much of which occurred at home during waking hours.

TL;DR: This study showed that over a 3-month period the use of sensor-augmented insulin-pump therapy with the threshold-suspend feature reduced nocturnal hypoglycemia, without increasing glycated hemoglobin values.